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The exponential growth in technological abilities and biological understanding of diseases result in
the advancement of novel interventions and therapeutics which may dramatically impact patients.
Despite this significant progress in biomedical science and technology, the efficiency of clinical
product development (i.e., drugs, medical devices, and medical procedures) is not improving
and may actually be decreasing. Innovations arising from medical research are nowadays facing
important hurdles that prevent their timely implementation into patient management, treatment
and health policies (1).
Although promotion of standards, recording and reporting information is a key stepping
stone to an effective and safe healthcare system, the high volume of bureaucracy hinders an
early introduction into the market (1–3). At the same time, the costs of drug development
continue to rise.
We require a team of stakeholders to translate the overwhelming rate of inventions into clinical
care (Figure 1). The five components of such a team are (1) The innovators, most commonly the
Academia, (2) Industry, key to fund and facilitate the innovation, (3) The research ethics board,
mostly located in clinical institutions and responsible for the safety of patients and society and (4)
The national/regional regulatory agencies which take into account ethical, feasibility and financial
aspects important for the ultimate implementation. The last (5) and perhaps the most important
stakeholder are the patients and their representatives.
This paper is a part of a Frontiers research topic entitled “The Silent Cry: How to Turn
Translational Medicine Toward Patients and Unmet Medical Needs” which is a larger series
collecting other position papers addressing issues related to early discovery, patenting, animal
work, preclinical and other aspects of clinical trials. Coming from the observation that translational
process is highly inefficient in the current healthcare state, this series was created to raise awareness
on the different hurdles of the process. The list of all topics developed in the silent cry series can be
found on the Frontiers webpage: (4). Nonetheless, the focus point of this article is the relationships
between the academic, the business, the ethical and the regulatory partners.
Together, the tension between potential benefits from innovation and the fallout upon mistakes
in safety, legal repercussions or financial loss results in a rough path of progress and frustrations for
all sides in this endeavor. For each of the partners there are specific benefits but most importantly
risks to be aware of. The unique risks for each partner result in delays and are considered
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FIGURE 1 | Stakeholders in translational medicine: common goals (in the circles) and specific concerns (in the braces).
bureaucratic hurdles in the translational medicine path. Only by
understanding the risks and benefits for each partner, a project
can be successful in a timely manner (5, 6).
In the present paper we lay out the individual concerns of each
partner as well as the common beneficial components (Figure 1),
which will potentially help improving the interactions and easing
the path to translate innovations into clinical practice. Other
major hurdles which exist in this path from early discovery
to clinical trial and ultimately implementation are discussed in
related articles to the silent cry series.
The initial stakeholders are the researchers who cherish the
invention as their own “child” and strive to get the discovery
published in a high impact journal while applying for funding. In
their view, the potential benefit to patients makes it “unethical”
not to proceed with patient interaction early on. It is common
that they overlook important steps such as patent, appropriate
financing, necessary technical and regulatory steps and ultimately
the distribution of the innovation to the public. This can affect the
maturation of their “child”.
Each business partner, on the other hand, needs to observe the
invention through the lens of financial gain. Protection of any
invention by intellectual property is necessary but by itself not
sufficient for industry to invest in the product. Unidentified risks
and lack of clear benefits can discourage the Industry partner
from joining this endeavor. Industry usually wants to see a
clear horizon of patient-numbers, benefits, safety and economic
value (e.g., will a drug warrant reimbursement by payers and
will it be beneficial enough to sell on the market). Therefore,
innovations in small populations such as most childhood diseases
are a major hurdle. Potentially small volumes of cases, possible
legal ramifications and reputational damage of adverse events in
children, competition with larger (adult) indication groups result
in tensions between the innovator and the business partner.
Although the mandate of the Instutional Review Board (IRB)
is to advance research in a safe and ethical way toward patient and
society, the institutional protection and avoidance of potential
individual law suits commonly interfere with this initial mission.
The more innovative and invasive the discovery, the higher is the
risk for the IRB. This tension creates automatically a higher need
for safety measures resulting in the much discussed bureaucratic
hurdles observed by the innovators. Furthermore, if potential
financial profit is involved, further tension raises between the IRB
and the industry partner.
Last but not least are the regulatory agencies responsible
for protecting the population from adverse events while also
considering both clinical and financial implications. Importantly,
the extensive testing for new therapeutics or medical devices
often represents large and risky financial commitments from
manufacturers (7). Only well established companies are able to
absorb these level of costs, which prevents new players from
entering the market competition. The risks without yet clear
long term benefit to the patients and society result in risk
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aversion even more so when approvals require additional steps,
time and costs in high-risk products. The tension between
the innovator/industry and the regulatory agencies is also
increased when the decision process is not transparent and/or the
individuals responsible for these decisions cannot be contacted.
In order to improve the integration between the
abovementioned four partners in this part of translational
medicine, it is important for all stakeholders to first appreciate
each partner’s roles and priorities, and to guarantee their
independency and role in the process. To achieve efficient
project progression it is essential to increase risk tolerance
and emphasize the potential short and long term benefits
to each partner. Specific tools to achieve these goals include
a “concierge service” which means early on involvement of
industry partnership and research collaboration experts. These
experts, speaking the same industry jargon, will know how and
when to approach the right business partners. They can also
be involved in the regulatory issues further in the process. One
should not hold back on approaching high up individuals in the
involved companies to ensure sustained partnership.
Many countries are moving into regional and nationwide IRB
agencies which will reduce diversity and increase transparency
in decision making and shorten times for large projects.
Involvement of innovators in the IRB committees and
continuous learning and discussions with IRB chairs will
also facilitate trust and reduce risk aversion. When approaching
the regulatory agencies, seeking experts and meeting the
individuals responsible for specific applications will result in
better and faster outcomes. The use of external experts and
advocates might also support this goal.
Finally, patient advocates (8, 9) are extremely important from
early on as they also play key role in the discussions with IRB and
regulatory agencies. They can guide the innovator and industry in
the priorities of the end users of the product. Specific care should
be spent on the role of smart (dynamic) consents covering the
current issues as well as the future potential use of patient data
and tissues. One should explore the potential collaborations with
industry and non-academic stakeholders.
When balancing technological innovations, new medical
concepts and deeper understanding of human biology
translational projects can transform disease management and
thereby improve patient outcome. Ethics, health and economics
are all at stake and therefore a careful approach including
participation of all stakeholders is required. Understanding the
risk and benefits for each partner in this journey and keeping
active representation of each of the partners in every decision
making step will reduce the tension and is the most fruitful
way forward.
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